Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis.
Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).

 

Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and the need of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) remain controversial.

The aim of this meta-analyzis was, on one hand, to assess the impact of the new-onset LBBB and PPI on all-cause mortality at one year and, on the other hand, to determine the new-onset LBBB predictive value on the need of PPI.

In all, this meta-analyzis included 17 studies with 11788 patients with data on the impact of the new-onset LBBB and the need of PPI. The new-onset LBBB post TAVI was associated with a greater need of PPI (RR 2.18; CI 95%, 1.28 to 3.70) and a higher risk of cardiac death (RR 1.39; CI 95% 1.04 to 1.86) as well as a tendency to increase all-cause mortality (RR 1.21; CI 95% 0.98 to 1.50).

The need of PPI post TAVI was not associated to an increase in all-cause mortality at one year (RR 1.03; CI 95% 0.9 to 1.18). In fact, it showed a tendency to have a protective effect against cardiac death (RR 0.78; CI 95% 0.60–1.03).

Conclusion
The new-onset left bundle branch block post TAVI is a risk marker of cardiac death and need of PPI at one year follow up. The need of PPI immediately post implantation, was not associated with an increase in mortality.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...